Distinguished in Primary Biliary Cholangitis

Dr. Hillel Tobias

Transplant Surgery | Gastroenterology | Internal Medicine
261 East 78th Street, 4th Floor, 
New York, NY 
On Staff At
59 Years of Experience
Distinguished in Primary Biliary Cholangitis
261 East 78th Street, 4th Floor, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hillel Tobias is an Internal Medicine specialist and a Transplant Surgeon in New York, New York. Dr. Tobias has been practicing medicine for over 59 years and is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Primary Biliary Cholangitis.

Graduate Institution
Washington University
Residency
New York University Langone Medical Center
Specialties
Transplant Surgery
Gastroenterology
Internal Medicine
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine/Gastroenterology
Fellowships
Mount Sinai Hospital and Medical Center
Hospital Affiliations
Hofstra/Northwell School Of Medicine/Nursing
Lenox Hill Hospital
Transplant Institute
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Northwell Health Center for Liver Disease and Transplantation
261 East 78th Street, 4th Floor, New York, NY 10075

Additional Areas of Focus

Dr. Tobias has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

2 Total Publications

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Journal: Hepatology (Baltimore, Md.)
Published: September 04, 2015
Similar Doctors
Advanced in Primary Biliary Cholangitis
Dr. Jonathan Schwartz
Gastroenterology
Advanced in Primary Biliary Cholangitis
Dr. Jonathan Schwartz
Gastroenterology

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (8.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Schwartz is a Gastroenterologist in Bronx, New York. Dr. Schwartz is rated as an Advanced provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Hepatitis, Primary Biliary Cholangitis, Reynolds Syndrome, and Budd-Chiari Syndrome.

James S. Park
Advanced in Primary Biliary Cholangitis
Dr. James S. Park
Transplant Surgery | Hepatology
Advanced in Primary Biliary Cholangitis
Dr. James S. Park
Transplant Surgery | Hepatology

Northwell Health Physician Partners Sandra Atlas Bass Center For Liver Diseases

400 Community Drive, 1st Floor, 
Manhasset, NY 
 (13.6 miles away)
516-562-4664
Languages Spoken:
English, Korean
See accepted insurances

James Park is a Hepatologist and a Transplant Surgeon in Manhasset, New York. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Hepatitis, Cirrhosis, Hepatitis C, Liver Transplant, and Gallbladder Removal.

Sanjaya K. Satapathy
Advanced in Primary Biliary Cholangitis
Dr. Sanjaya K. Satapathy
Transplant Surgery | Hepatology
Advanced in Primary Biliary Cholangitis
Dr. Sanjaya K. Satapathy
Transplant Surgery | Hepatology

Northwell Health Physician Partners Sandra Atlas Bass Center For Liver Diseases

400 Community Drive, 1st Floor, 
Manhasset, NY 
 (13.6 miles away)
516-562-4664
Languages Spoken:
English, Hindi
See accepted insurances
Offers Telehealth

Sanjaya Satapathy is a Hepatologist and a Transplant Surgeon in Manhasset, New York. Dr. Satapathy is rated as an Elite provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Spontaneous Bacterial Peritonitis, Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Liver Transplant, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tobias's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 8 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile